DocuSign Clears Analyst Target; Insiders Sold Lower
DocuSign's stock rallied to $77.61 on a new SAP distribution deal, clearing the consensus analyst target of $70.37. But insiders sold $4.38 million in shares during the run, with CRO Hansen clearing i
DocuSign Clears Analyst Target; Insiders Sold Lower
NEW YORK, November 8 —
DocuSign, Inc. (DOCU) cleared the consensus analyst price target on the strength of a new SAP-branded distribution deal, reaching $77.61. The CEO, CRO, CLO, and President of Growth sold a combined $4.38 million in shares from September through November, net purchases zero. The most widely followed fair value estimate sits 27% below the current close.
- DOCU at $77.61 trades 10.3% above the $70.37 consensus target; one widely followed fair value estimate puts it at $60.99.
- CEO sold 26,250 shares at $68.53, $69.98 Oct. 1; CRO Hansen sold again at $81.82 Nov. 2, above the consensus target.
Two Distribution On-Ramps
DocuSign, Inc. sells e-signature software and an AI-powered agreement management platform: Contract Lifecycle Management, Document Generation, Notary, and identity verification, connecting enterprise contracts to the systems that execute them. The SAP deal is the structural argument for the rally. Agreement management tools for SAP Sales Cloud and SAP SuccessFactors will be sold as SAP-branded Solution Extensions, reaching SAP's global customer base through native distribution. A parallel Salesforce integration, also recently launched, adds a second major channel. Combined, the moves place DocuSign's platform inside two of enterprise software's largest installed bases, the cleaner argument for why a 9.4% revenue grower now trades above analyst consensus.
The CRO Sold Higher
Five executives and three board directors sold a net $4.38 million over the 90 days ending early November, against zero purchases, per filings. CEO Allan Thygesen sold 26,250 shares on October 1 at $68.53, $69.98, roughly 10% below today's close, in three open-market tranches. The more pointed data point belongs to Chief Revenue Officer Paula Hansen: having sold 3,300 shares near $69 on October 1, she sold another 3,300 at $81.82 on November 2, above both the consensus target and today's $77.61 close. The CRO, whose SAP and Salesforce partnerships anchor the bull case, cleared inventory at a price the stock has since given back.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| DOCU | $14.5B | 14.9x | +11.4% |
| ZM | $26.2B | 14.2x | +8.1% |
| TDOC | $1.6B | n/a | +16.9% |
| TWLO | $31.3B | 29.5x | +54.7% |
| OKTA | $29.5B | 38.5x | +96.8% |
| ROKU | $23.9B | 40.1x | +52.9% |
What Revenue Growth Must Do
The bull case requires the SAP and Salesforce distribution agreements to push revenue growth past the current 9.4% annual pace, a scenario investors can stress-test with the DCF calculator. But the five-year total return stands at negative 70.68%, sitting uneasily beside a 90-day rally priced above analyst consensus. Run the free DocuSign, Inc. deep-dive for updated numbers before the next earnings print.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did DocuSign stock rally above analyst targets?
A new SAP distribution deal provided the catalyst. DocuSign's agreement management tools will be sold as SAP-branded Solution Extensions, reaching SAP's global customer base through native distribution. A parallel Salesforce integration, also recently launched, provides a second major distribution channel.
Did DocuSign insiders buy or sell shares recently?
Five executives and three board directors sold a net $4.38 million in shares over the 90 days ending early November, against zero purchases. CRO Hannah sold 3,300 shares on November 2 at $81.82, above both the consensus analyst target of $70.37 and the current stock price of $77.61.
What is DocuSign's financial health?
TTM revenue is $3.36 billion growing 9.4%, with free cash flow of $1.313 billion on a 79.6% gross margin. The company has $780 million in cash against $180 million in debt, providing financial cushion for operations and growth investment.
Has DocuSign beaten earnings expectations?
Yes. DocuSign has beaten EPS estimates in each of the past four quarters, most recently reporting $1.16 actual earnings versus $1.086 expected in its September 3 8-K filing.
What concerns does the bear case raise?
A widely followed fair value estimate places the stock at $60.99, 27% below the current close of $77.61. The five-year total return stands at negative 70.68%, sitting uneasily beside a 90-day rally now priced above analyst consensus.
DocuSign shares have surged 28.79% over the past 90 days to $77.61, pushing the stock above the consensus analyst price target of $70.37, partly on a new SAP-branded distribution agreement for its agreement management platform. What makes the rally harder to read: the company's CEO, CRO, CLO, and President of Growth all sold a combined $4.38 million in shares during the same window, most of them at prices well below where the stock trades today.